This technology is an immunosuppressant that suppresses T cell proliferation and can be used to treat organ transplant rejection and autoimmune or inflammatory conditions.
This technology is a small molecule that selectively targets the mitogen-activated protein kinase (MAPK) core pathways, regulated by Germinal Center Kinase (GCK), and inhibits cell growth for treatment of cancers, notably multiple myeloma.
This technology identifies a key pathway involved in the development of malignant cells associated with multiple myeloma and demonstrates that its inhibition is a promising strategy for treating the disease.
